Aligos Q2 FY26 net loss narrows 91% to $1.5 million

Reuters2026/08/06 12:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Aligos Therapeutics posted a Q2 net loss of $1.5 million, narrowing from a $15.9 million loss a year earlier; loss per share improved to $(0.14).
R&D expense climbed to $24.1 million from $14 million, driven by higher third-party costs for the pevifoscorvir sodium Phase 2 trial.
Cash, cash equivalents and investments fell to $30.4 million at June 30 from $77.8 million at Dec. 31, excluding a $25 million upfront received in July.
Quarter results included $3 million of income from changes in fair value of 2023 common warrants, while interest and other income slipped to $0.2 million from $1.2 million.
Enrollment finished in the Phase 2 B-SUPREME study of pevifoscorvir sodium; Aligos expects topline data in late Q3 2027 and sees funding through Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-005294), on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Aligos Q2 FY26 net loss narrows 91% to $1.5 million

You may also like

Crypto prices